FURTHER READING

FURTHER READING

Baumgart DC, LeBerre C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N Engl J Med 2021; 385 : 1302–15. Brown SR, Fearnhead NS, Faiz OD et al . The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease. Colorectal Dis 2018; 20 (Suppl 8): 3–117. Colombel JF , Sandborn WJ, Rutgeerts P et al . Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132 (1): 52–65. Cottrill M. BSG updates guidance on ulcerative colitis and Crohn’s disease. Available from https://www .guidelinesinpractice.co.uk/ gastrointestinal/bsg-updates-guidance-on-ulcerative-colitis-and - cr ohns-disease/300702.article (accessed 7 October 2021). Dinesen LC, Walsh AJ, Protic MN et al . The pattern and outcome of acute severe colitis. J Crohns Colitis 2010; 4 (4): 431–7. Panés J, Garcia-Olmo D, van Assche G et al . Long-term e ffi cacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology 2018; 154 : 1334– 1342.e4. Ran Z, Wu K, Matsuoka K et al . Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol 2021; 36 : 637–45. Sands BE, Anderson FH, Bernstein CN et al . Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350 (9): 876–85. Wasmann K, de Groof EJ, Stellingwerf ME et al . Treatment of perianal fistulas in Crohn’s disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): a randomised controlled trial. J Crohns Colitis 2020; 14 : 1049–56.